The trip to Mars just got a little more difficult now that French researchers have discovered that antibodies used to fight off disease might become seriously compromised during long-term space flight. In a new report published online in the FASEB Journal (http://www.fasebj.org), the scientists show that antibodies produced in space are less effective than those produced on terra firma. The reduced effectiveness of antibodies makes astronauts more susceptible to illness, while increasing the danger posed by bacteria and viruses likely to coexist with wayfaring astronauts.
“We hope to find efficient pharmacological and/or nutritional countermeasures to alterations of the immune system that could be useful to astronauts and to people who have weak immune systems on Earth because of infections, aging, or chronic stress exposure,” said Jean-Pol Frippiat, a researcher involved in the work from the Faculty of Medicine, Development and Immunogenetics at the Universite Henri Poincare-Nancy, Vandoeuvre-les-Nancy, France.
To make their discovery, Frippiat and colleagues conducted studies using three groups of amphibians. Amphibians were chosen for the work because they use the same cellular mechanisms to produce antibodies as humans do. The first group of amphibians was immunized in space, the second was immunized on Earth, and the third was not immunized at all. Comparison of the antibodies produced revealed that the quality of the antibodies generated by the group immunized in space was decreased. This suggests that spaceflight conditions alter the immune system and affect its ability to protect against infections and tumors, posing a serious risk for astronauts.
“This paper shows that somatic hypermutation occurs at a lower frequency in spaceflight and brings together yet more evidence that the immune system is dependent on gravity,” said Millie Hughes-Fulford, Ph.D., NASA Science Astronaut; Professor, Department of Biochemistry and Biophysics, UCSF; Director, Laboratory of Cell Growth, VAMC/UCSF; and editorial board member of the FASEB Journal. “Dependence on gravity should be no surprise since all of earth’s jawed vertebrates developed in earth’s gravity, and it would be logical to expect that some systems would require gravity for normal function.”
“Outer space may be the final frontier, but this research shows that our inner space could pose the greatest threat to the success of a mission,” said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. “These explorers will have to be prepared not only for the challenges of extremely hostile environments, but also those posed by microbial stowaways, even those with which we peacefully co-exist on Earth.”
###
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB) and celebrates its 25th anniversary in 2011. Over the past quarter century, the journal has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century and is the most cited biology journal worldwide according to the Institute for Scientific Information.
FASEB comprises 23 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. FASEB enhances the ability of scientists and engineers to improve–through their research–the health, well-being and productivity of all people. FASEB’s mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy. Details: Matthieu Bascove, Nathan Gueguinou, Berenice Schaerlinger, Guillemette Gauquelin-Koch, and Jean-Pol Frippiat. Decrease in antibody somatic hypermutation frequency under extreme, extended spaceflight conditions. FASEB J. published ahead of print, May 18, 2011, doi: 1096/fj.11-185215 ; http://www.fasebj.org/content/early/2011/05/16/fj.11-185215.abstract
